Cologne-based AYOXXA Biosystems GmbH, active in the development of multiplex protein analysis assays for drug discovery and translational research, today announced the successful closing of a financing round which will provide runway for the coming 3 - 5 years. The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network.

The funds will be used to drive the global commercialization of AYOXXA's LUNARIS™ platform. The platform is designed to generate high-quality proteomics data using smallest-volume samples. It enables fully scalable quantitative validation of disease-relevant biomarkers and allows for translational research “from laboratory to clinic, from mouse model to human, from data to treatment or vaccine” as the company puts it.

"We are proud to have attracted Prosnav Capital as a shareholder. Prosnav provides the company with a solid perspective, not only in terms of funding, but also with their valuable relationships and experience, especially in Asia," said Dr. Albrecht Läufer, AYOXXA's Chief Executive Officer. "With our LUNARIS™ platform, AYOXXA is well positioned to enter the commercial growth phase."

Continuing investors led by Wellington Partners and NRW.Bank include b-to-v Partners S.à.r.l.; Rainer Christine Asset Management GmbH.; Equivation-Beteiligungsgesellschaft mbH; Roland Oetker Family Office; Riesner Verwaltungs GmbH, the two Co-Founders of AYOXXA and several other private investors.